Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.
From cancer immunotherapy and antibiotics to GMO crops and pandemic surveillance, gain of function is a cornerstone of basic research.
The cellular therapy depletes CD19-positive B cells with the goal of 'resetting' the immune system to achieve durable remission.
Janssen Biotech has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
Bristol Myers Squibb will boost its cell therapy manufacturing network with in-house viral vector production thanks to the acquisition of Novartis’ Libertyville, Illinois facility.